Abstract
Background: Community Acquired Pneumonia (CAP) is leading cause of morbidity and mortality in all age groups globally. 4 million cases of Community Acquired Pneumonia occur annually. Haemophilus influenzae is a causative organism of CAP. Empirical treatment with antibiotics like levofloxacin and azithromycin is recommended in these cases. Objectives: This study was conducted to evaluate the minimum inhibitory concentration of levofloxacin and azithromycin in H. influenzae isolates from respiratory specimens. Design: Minimum inhibitory concentrations of levofloxacin and azithromycin in 40 clinically significant H.influenzae isolates were tested using E-test method after the approval of Institutional Ethics committee. The results were analyzed according to 2019 CLSI guidelines. Result: MIC50 for levofloxacin was 0.008 µg/ml, MIC90 1.5 µg/ml and the 3 resistant isolates had MIC ranging between 8 and 12 µg/ml. Azithromycin MIC50 was 0.047µg/ml, MIC90 6.4 µg/ml and 5 resistant isolates had MIC between 6 and 32µg/ml. Conclusion: The rising MIC of levofloxacin and azithromycin in H.influenzae emphasizes the need to monitor the antibiotic susceptibility pattern on a regular basis. It is also advisable to restrain the use of fluoroquinolones to make it available for use in the tuberculosis treatment and also to avoid any adverse effects.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Indian Journal of Public Health Research & Development
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
